You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

CLINICAL TRIALS PROFILE FOR HALOBETASOL PROPIONATE; TAZAROTENE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for HALOBETASOL PROPIONATE; TAZAROTENE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04720105 ↗ Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis Recruiting Bausch Health Americas, Inc. Phase 4 2020-11-19 The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.
NCT04720105 ↗ Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis Recruiting Icahn School of Medicine at Mount Sinai Phase 4 2020-11-19 The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.
NCT05282771 ↗ A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis. Completed Taro Pharmaceuticals USA Early Phase 1 2021-04-16 To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (Reference Listed Drug) in the treatment of moderate to severe plaque psoriasis.
NCT06042647 ↗ Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis Completed Dermatology Consulting Services, PLLC Phase 4 2023-07-13 The objective of this research is to demonstrate superior anti-inflammatory effects, as demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate 0.05% cream.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for HALOBETASOL PROPIONATE; TAZAROTENE

Condition Name

Condition Name for HALOBETASOL PROPIONATE; TAZAROTENE
Intervention Trials
Plaque Psoriasis 2
Palmoplantar Psoriasis 1
Psoriasis Vulgaris 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for HALOBETASOL PROPIONATE; TAZAROTENE
Intervention Trials
Psoriasis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for HALOBETASOL PROPIONATE; TAZAROTENE

Trials by Country

Trials by Country for HALOBETASOL PROPIONATE; TAZAROTENE
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for HALOBETASOL PROPIONATE; TAZAROTENE
Location Trials
North Carolina 2
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for HALOBETASOL PROPIONATE; TAZAROTENE

Clinical Trial Phase

Clinical Trial Phase for HALOBETASOL PROPIONATE; TAZAROTENE
Clinical Trial Phase Trials
Phase 4 2
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for HALOBETASOL PROPIONATE; TAZAROTENE
Clinical Trial Phase Trials
Completed 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for HALOBETASOL PROPIONATE; TAZAROTENE

Sponsor Name

Sponsor Name for HALOBETASOL PROPIONATE; TAZAROTENE
Sponsor Trials
Bausch Health Americas, Inc. 1
Icahn School of Medicine at Mount Sinai 1
Taro Pharmaceuticals USA 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for HALOBETASOL PROPIONATE; TAZAROTENE
Sponsor Trials
Industry 2
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.